Xolair 150 MG/ML syringeml
Ended Awarded Last action
- Contract number
- SPE2DR26FCHU0
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $12,634
Award facts
- Contract value 100% obligated
- $12,633.76 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $12,633.76 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xolair 150 mg/ml syringes. The delivery order, issued on December 5, 2025, with an ultimate completion date of December 29, 2025, utilizes firm fixed-price pricing with no set-aside designation. DMS Pharmaceutical Group Inc. competed for this award based on its established capabilities as a critical pharmaceutical supplier within the federal supply chain.
This delivery order was issued under DMS Pharmaceutical Group's Indefinite Delivery Contract (IDC) with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative. The parent IDC, designated SPE2DR and valued at $499,999,999, was awarded on November 13, 2025, and positions DMS Pharmaceutical Group as a regional prime vendor contractor supporting Department of Defense medical supply requirements through 2036. The PPV-G GEN V represents a $30.3 billion acquisition strategy designed to enable the Defense Logistics Agency to issue delivery orders for comprehensive pharmaceutical and medical consumable products to support military healthcare facilities worldwide. As a single-award IDC holder under this program, DMS Pharmaceutical Group serves as a key supplier of branded and generic prescription medications, biologics, and specialty pharmaceuticals for DoD healthcare operations globally.
Quick answers
Who was awarded contract SPE2DR26FCHU0?
SPE2DR26FCHU0 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 5, 2025.
How much is contract SPE2DR26FCHU0 worth?
The government has obligated $12,634 on SPE2DR26FCHU0.
Is contract SPE2DR26FCHU0 an order under another contract?
Yes. SPE2DR26FCHU0 is a delivery order under SPE2DR25D9113, an indefinite delivery contract.
Was contract SPE2DR26FCHU0 competed?
The extent of competition for SPE2DR26FCHU0 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award